Bone Therapeutics reports positive interim efficacy results in the 16-patient Phase I/IIA study of ALLOB® allogeneic bone cell therapy in the treatment of delayed-union fractures.
At six months following one percutaneous dose of ALLOB to the fracture site, all patients met the primary endpoint and exhibited statistically significant clinical and radiological improvements. Recruitment will end early based on this interim data which, combined with recent successful results in spinal fusion, establishes ALLOB as a strong product candidate for the company's pipeline.
The next clinical phase will involve further development for ALLOB in difficult fractures. Notably, given the close relationship between the delayed-union and non-union indications, the company will also cease recruitment in the PREOB® non-union trial to focus resources on ALLOB.
Sources: Bone Therapeutics SA; ORTHOWORLD Inc.